Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMS III Stroke Trial
NCT00359424Phase 3Terminated
- Start
- Aug 2006
- Primary completion
- Jul 2012
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of tissue-plasminogen activator in ischemic stroke (2 arms). Primary endpoints: Modified Rankin Scale Score Dichotomized to 0-2 Versus Greater Than 2 at 90 days, Death Due to Any Cause at 90 days and 1 more. Started Aug 2006; status: terminated.
02
Drugs
tissue-plasminogen activator
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT00359424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00359424.